Protagonist Therapeutics, Inc Basic Shares Outstanding (Weighted Average)
Protagonist Therapeutics, Inc (PTGX) reported Basic Shares Outstanding (Weighted Average) of 65.94 million shares for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:WeightedAverageNumberOfSharesOutstandingBasic · last filed 2026-08-05
- Protagonist Therapeutics, Inc weighted average number of shares outstanding, basic for the quarter ending 2026-06-30 was 65.94M shares, a 3.82% increase year-over-year.
- Protagonist Therapeutics, Inc weighted average number of shares outstanding, basic for the quarter ending 2026-03-31 was 65.09M shares, a 3.37% increase year-over-year.
- Protagonist Therapeutics, Inc weighted average number of shares outstanding, basic for the quarter ending 2025-12-31 was 64.04M shares, a 2.73% increase year-over-year.
- Protagonist Therapeutics, Inc weighted average number of shares outstanding, basic for the quarter ending 2025-09-30 was 63.77M shares, a 3.25% increase year-over-year.
- Protagonist Therapeutics, Inc weighted average number of shares outstanding, basic for fiscal 2025 was 63.57M shares, a 3.26% increase from fiscal 2024.
- Protagonist Therapeutics, Inc weighted average number of shares outstanding, basic for fiscal 2024 was 61.57M shares, a 8.46% increase from fiscal 2023.
- Protagonist Therapeutics, Inc weighted average number of shares outstanding, basic for fiscal 2023 was 56.76M shares, a 15.74% increase from fiscal 2022.
- Protagonist Therapeutics, Inc weighted average number of shares outstanding, basic for fiscal 2022 was 49.04M shares, a 5.87% increase from fiscal 2021.
| Period end | Weighted Average Number of Shares Outstanding, Basic 3 month | Weighted Average Number of Shares Outstanding, Basic 6 month | Weighted Average Number of Shares Outstanding, Basic 9 month | Weighted Average Number of Shares Outstanding, Basic 12 month |
|---|---|---|---|---|
| 2026-06-30 | 65.94M shares 10-Q · filed 2026-08-05 | 65.51M shares 10-Q · filed 2026-08-05 | 65.02M shares derived: average of 3 quarters · filed 2026-08-05 | 64.71M shares derived: average of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | 65.09M shares 10-Q · filed 2026-05-05 | 64.56M shares derived: average of 2 quarters · filed 2026-05-05 | 64.30M shares derived: average of 3 quarters · filed 2026-05-05 | 64.10M shares derived: average of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | 64.04M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | 63.90M shares derived: average of 2 quarters · filed 2026-02-25 | 63.77M shares derived: average of 3 quarters · filed 2026-08-05 | 63.57M shares 10-K · filed 2026-02-25 |
| 2025-09-30 | 63.77M shares 10-Q · filed 2025-11-06 | 63.64M shares derived: average of 2 quarters · filed 2026-08-05 | 63.42M shares 10-Q · filed 2025-11-06 | 63.15M shares derived: average of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | 63.51M shares 10-Q · filed 2026-08-05 | 63.24M shares 10-Q · filed 2026-08-05 | 62.94M shares derived: average of 3 quarters · filed 2026-08-05 | 62.64M shares derived: average of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | 62.96M shares 10-Q · filed 2026-05-05 | 62.65M shares derived: average of 2 quarters · filed 2026-05-05 | 62.36M shares derived: average of 3 quarters · filed 2026-05-05 | 62.09M shares derived: average of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | 62.33M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | 62.05M shares derived: average of 2 quarters · filed 2026-02-25 | 61.80M shares derived: average of 3 quarters · filed 2026-02-25 | 61.57M shares 10-K · filed 2026-02-25 |
| 2024-09-30 | 61.77M shares 10-Q · filed 2025-11-06 | 61.54M shares derived: average of 2 quarters · filed 2025-11-06 | 61.31M shares 10-Q · filed 2025-11-06 | 61.09M shares derived: average of 4 quarters · filed 2026-02-25 |
| 2024-06-30 | 61.31M shares 10-Q · filed 2025-08-06 | 61.08M shares 10-Q · filed 2025-08-06 | 60.86M shares derived: average of 3 quarters · filed 2026-02-25 | 60.44M shares derived: average of 4 quarters · filed 2026-02-25 |
| 2024-03-31 | 60.86M shares 10-Q · filed 2025-05-06 | 60.64M shares derived: average of 2 quarters · filed 2026-02-25 | 60.16M shares derived: average of 3 quarters · filed 2026-02-25 | 59.31M shares derived: average of 4 quarters · filed 2026-02-25 |
| 2023-12-31 | 60.43M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | 59.80M shares derived: average of 2 quarters · filed 2026-02-25 | 58.80M shares derived: average of 3 quarters · filed 2026-02-25 | 56.76M shares 10-K · filed 2026-02-25 |
| 2023-09-30 | 59.18M shares 10-Q · filed 2024-11-07 | 57.98M shares derived: average of 2 quarters · filed 2024-11-07 | 55.54M shares 10-Q · filed 2024-11-07 | 53.95M shares derived: average of 4 quarters · filed 2025-02-21 |
| 2023-06-30 | 56.78M shares 10-Q · filed 2024-08-06 | 53.69M shares 10-Q · filed 2024-08-06 | 52.20M shares derived: average of 3 quarters · filed 2025-02-21 | 51.43M shares derived: average of 4 quarters · filed 2025-02-21 |
| 2023-03-31 | 50.57M shares 10-Q · filed 2024-05-07 | 49.91M shares derived: average of 2 quarters · filed 2025-02-21 | 49.65M shares derived: average of 3 quarters · filed 2025-02-21 | 49.50M shares derived: average of 4 quarters · filed 2025-02-21 |
| 2022-12-31 | 49.25M shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-21 | 49.18M shares derived: average of 2 quarters · filed 2025-02-21 | 49.14M shares derived: average of 3 quarters · filed 2025-02-21 | 49.04M shares 10-K · filed 2025-02-21 |
| 2022-09-30 | 49.11M shares 10-Q · filed 2023-11-02 | 49.08M shares derived: average of 2 quarters · filed 2023-11-02 | 48.97M shares 10-Q · filed 2023-11-02 | 48.77M shares derived: average of 4 quarters · filed 2024-02-27 |
| 2022-06-30 | 49.05M shares 10-Q · filed 2023-08-03 | 48.90M shares 10-Q · filed 2023-08-03 | 48.66M shares derived: average of 3 quarters · filed 2024-02-27 | 48.49M shares derived: average of 4 quarters · filed 2024-02-27 |
| 2022-03-31 | 48.75M shares 10-Q · filed 2023-05-04 | 48.46M shares derived: average of 2 quarters · filed 2024-02-27 | 48.30M shares derived: average of 3 quarters · filed 2024-02-27 | 47.44M shares derived: average of 4 quarters · filed 2024-02-27 |
| 2021-12-31 | 48.17M shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | 48.08M shares derived: average of 2 quarters · filed 2024-02-27 | 47.01M shares derived: average of 3 quarters · filed 2024-02-27 | 46.32M shares 10-K · filed 2024-02-27 |
| 2021-09-30 | 47.99M shares 10-Q · filed 2022-11-08 | 46.43M shares derived: average of 2 quarters · filed 2022-11-08 | 45.71M shares 10-Q · filed 2022-11-08 | |
| 2021-06-30 | 44.86M shares 10-Q · filed 2022-08-04 | 44.55M shares 10-Q · filed 2022-08-04 | ||
| 2021-03-31 | 44.22M shares 10-Q · filed 2022-05-05 | |||
| 2020-12-31 | 34.40M shares 10-K · filed 2023-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |